Ankündigung • Mar 13
Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. completed the acquisition of Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F). Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F) on November 12, 2024. As part of the transaction, Charme was to acquire all of the issued and outstanding share capital of Centogene GmbH. The consideration consists of €8.7 million in cash and an undisclosed amount in the assumption of debt of Centogene N.V. In connection with the transaction, Centogene GmbH will receive funding, secured by Saudi accounts receivables, from its Saudi Arabian joint venture Genomics Innovations Company Limited to provide it liquidity to the closing date, and the Company shall be relieved of all existing liabilities owing to the Company’s senior secured lender Oxford Finance LLC. Deutsche Private Equity DPE, TVM Capital, and Care Ventures, as well as all the Managing Directors of Centogene N.V. have irrevocably undertaken on customary terms and conditions to vote their respective shares in favor of the resolutions.
The transaction is subject to approval by regulatory requirements in Saudi Arabia, the execution and effectiveness of agreements to transfer to Centogene GmbH all of the Company’s equity and commercial interests in the JV, the assumption by Charme’s affiliate of all of the Company’s rights, obligations and liabilities under the existing Convertible Loan Agreement between the Company and Pharmaceutical Investment Company and the execution and effectiveness of an amendment and restatement of the Company’s existing Loan and Security Agreement with Oxford pursuant to which Charme’s affiliate will become party to the Loan and Security Agreement and the Company will be relieved of all rights, obligations and liabilities thereunder and approval of shareholders of Centogene N.V. The Management Board and Supervisory Board of Centogene N.V. have unanimously approved and recommends the shareholders to vote for the proposed transaction. The transaction is expected to close in the first quarter of 2025.
As of December 4, 2024, Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), has revealed the outcomes of its Extraordinary General Meeting. The shareholders have approved all the proposals, including the anticipated sale and transfer of Centogene GmbH to Charme Capital Partners Limited, a private equity firm operating across Europe.
Paul van der Bijl of NautaDutilh N.V. acted as legal advisor to Centogene N.V. Jan-Hendrik Horsmeier and Stephanie Horowitz of Clifford Chance LLP acted as legal advisor to Charme Capital Partners.
Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. completed the acquisition of Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F) on March 12, 2025. Ankündigung • Jan 13
Centogene N.V. Announces Resignation of Peter Bauer as Member of the Management Board, Effective as of June 30, 2025 On December 24, 2024, Peter Bauer, M.D. notified the Supervisory Board of Centogene N.V. of his resignation from his position as a member of the Management Board, effective as of June 30, 2025. Ankündigung • Nov 15
Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F). Charme IV Fund, a fund managed by Charme Capital Partners SGR S.p.A. agreed to acquire Centogene GmbH from Centogene N.V. (OTCPK:CNTG.F) on November 12, 2024. As part of the transaction, Charme was to acquire all of the issued and outstanding share capital of Centogene GmbH. The consideration consists of €8.7 million in cash and an undisclosed amount in the assumption of debt of Centogene N.V. In connection with the transaction, Centogene GmbH will receive funding, secured by Saudi accounts receivables, from its Saudi Arabian joint venture Genomics Innovations Company Limited to provide it liquidity to the closing date, and the Company shall be relieved of all existing liabilities owing to the Company’s senior secured lender Oxford Finance LLC. Deutsche Private Equity DPE, TVM Capital, and Care Ventures, as well as all the Managing Directors of Centogene N.V. have irrevocably undertaken on customary terms and conditions to vote their respective shares in favor of the resolutions.
The transaction is subject to approval by regulatory requirements in Saudi Arabia, the execution and effectiveness of agreements to transfer to Centogene GmbH all of the Company’s equity and commercial interests in the JV, the assumption by Charme’s affiliate of all of the Company’s rights, obligations and liabilities under the existing Convertible Loan Agreement between the Company and Pharmaceutical Investment Company and the execution and effectiveness of an amendment and restatement of the Company’s existing Loan and Security Agreement with Oxford pursuant to which Charme’s affiliate will become party to the Loan and Security Agreement and the Company will be relieved of all rights, obligations and liabilities thereunder and approval of shareholders of Centogene N.V. The Management Board and Supervisory Board of Centogene N.V. have unanimously approved and recommends the shareholders to vote for the proposed transaction. The transaction is expected to close in the first quarter of 2025.
Paul van der Bijl of NautaDutilh N.V. acted as legal advisor to Centogene N.V. Jan-Hendrik Horsmeier and Stephanie Horowitz of Clifford Chance LLP acted as legal advisor to Charme Capital Partners. Ankündigung • Oct 12
Centogene N.V. Announces Term Expires of Jose Miguel Coego Rios as Chief Financial Officer Centogene N.V. (the Company) previously announced that the Service Agreement between the Company and Jose Miguel Coego Rios, the Company's former Chief Financial Officer, would expire by its terms on September 30, 2024. On October 7, 2024, the Company and Mr. Rios entered into a Consultancy Agreement, which was deemed effective as of October 1, 2024, pursuant to which Mr. Rios will provide business consulting services to the Company in accordance with the terms of the Consultancy Agreement until no later than December 31, 2024. Ankündigung • Sep 26
Centogene N.V Announces Data from the Rostock International Parkinson's Disease (ROPAD) Centogene N.V announced data from the Company’s Rostock International Parkinson's Disease (ROPAD), further supporting the association of a RAB32 gene mutation with Parkinson's disease (PD). The study, published in The Lancet Neurology, builds on research from Emil K. Gustavsson and colleagues, who previously identified the RAB32 c.213C>G (p.Ser71Arg; dbSNP rs200251693) variant as a novel monogenic cause of PD. In the ROPAD Study, Whole Genome Sequencing (WGS) data from 3,354 PD patients revealed that nine patients from Germany, Italy, Spain, and Türkiye carried the RAB32 c.213C>G mutation. This proportion of variant-positives — 0.3% of the cohort — is significantly higher than the 0.002% found in general population databases such as the Genome Aggregation Database. Key Findings: Nine ROPAD participants (0.3% of the cohort) were heterozygous for the RAB32 c.213C>G mutation, supporting the mutation's causal role in Parkinson’s disease Age at onset in mutation-positives and mutation-negatives did not differ, while gender proportions and certain clinical characteristics did. The RAB32 Ser71Arg-associated haplotype was as in the Gustavsson et al. study, supportive of a single founder mutational event These findings underscore the importance of RAB32 as an important cause of Parkinson's disease. Ankündigung • Aug 02
Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors Centogene N.V. announced data from the Company’s Rostock International Parkinson's Disease (ROPAD) Study revealing the genetic factors and prevalence of Parkinson’s disease (PD). The findings from this landmark study indicate that approximately 15% of PD-related cases are tied to genetic variants, with the majority being linked to LRRK2 and GBA1. The research investigated variants in 50 genes with either an established relevance for PD or possible phenotypic overlap from over 12,500 patients from 16 countries who have been enrolled in CENTOGENE’s ROPAD Study. In more than 1,800 participants, a PD-relevant genetic test (PDGT) provided a positive result. This included variants linked to the LRRK2 and GBA1 genes, as well as PRKN, SNCA, and PINK1, or a combination of genetic findings in multiple genes. In the emerging era of gene-targeted PD clinical trials, the Company’s findings that approximately 15% of patients harbor potentially actionable genetic variants offers an important prospect to affected individuals and their families and underlines the need for genetic testing in PD patients. By capturing such genetic data, this also allows for differential genetic counselling across the spectrum of different ages at onset and family histories. The Company recently launched a ROPAD Consortium to continue driving PD research and treatment through collaborative efforts. The ROPAD Consortium will build on the vast network of neurologists, existing partnerships with non-profit organizations, and the largest genetic testing program for PD patients worldwide to streamline access to critical data, drive impactful research, and improve the potential for advancing treatment options. The Rostock International Parkinson's Disease (ROPAD) Study is a global epidemiological study focusing on the role of genetics in Parkinson’s disease (PD). The major goal of the study is to characterize the genetics of PD to establish a better understanding of the disease etiology, diagnosis, and severity. CENTOGENE utilizes CentoCard®, the Company’s proprietary, CE-marked Dried Blood Spot (DBS) collection kit in combination with state-of-the-art sequencing technologies to screen for mutations in LRRK2 and other PD-associated genes. To date, over 18,000 participants from around the world have been tested over a five-year period. Ankündigung • May 17
Centogene N.V. Provides Earnings Guidance for the Year 2024 Centogene N.V. provided earnings guidance for the year 2024, For the period, the company expects revenue growth to be between 10-15% in FY2024 compared to FY2023. Ankündigung • May 11
Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients Centogene N.V. revealed significant growth in the CENTOGENE Biodatabank, the world’s largest real-world data repository for rare and neurodegenerative diseases. Analysis of this patient data enables precise diagnosis of disease, identification of new genetic variants, and potential de-risking of drug development. The number of analyzed patient cases has grown by 13% to more than 850,000 patients as of December 31, 2023, compared to December 21, 2022, and the number of total unique variants has increased by 19% to over 850,000,000. This includes patients from over 120 countries, over 70% of whom are of non-European descent, underscoring the ethnic diversity of CENTOGENE’s knowledgebase. Ankündigung • May 03
Centogene N.V. announced delayed 20-F filing On 05/01/2024, Centogene N.V. announced that they will be unable to file their next 20-F by the deadline required by the SEC. New Risk • Mar 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€29m free cash flow). Negative equity (-€15m). Earnings are forecast to decline by an average of 5.7% per year for the foreseeable future. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (€47m net loss next year). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Market cap is less than US$100m (US$18.1m market cap). Ankündigung • Jan 18
Centogene N.V. Provides Earnings Guidance for the Full Year 2023 Centogene N.V. announced preliminary unaudited revenue for full year 2023 between approximately €48.5 million and €49.0 million, reflecting a growth rate over 2022 in the mid-single digits. Ankündigung • Dec 18
Centogene N.V. Announces Changes to Supervisory Board Centogene N.V. announced Andreas Busch’s and Holger Friedrich’s decision to resign from the Company’s Supervisory Board, effective December 12, 2023. Their respective resignations were not the result of any disagreement with the Company, and are in alignment with the Company’s previously announced intention on June 27, 2023, that two representatives from Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF), will join CENTOGENE’s Supervisory Board. Ankündigung • Dec 14
Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone Centogene N.V. announced the company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia (FTD). The EFRONT Study has been conducted with support from Alector, a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases, including FTD. Having met this milestone, CENTOGENE will continue to work with its extensive network of 30,000 physicians and enroll patients in the EFRONT Study under its Cento-FTD Program to provide timely diagnosis and further unlock insights into this neurodegenerative disorder. Ankündigung • Nov 15
Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism Centogene N.V. announced the discovery of a new form of early-onset dystonia and parkinsonism in the context of neurodevelopmental abnormalities associated to the gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) as part of an international team of researchers. The study's findings have been published in Brain, a leading, peer-reviewed scientific journal of neurology. The study reports on 45 patients from 29 families and provides evidence that bi-allelic pathogenic variants in the ACBD6 gene lead to a distinct neurodevelopmental syndrome accompanied by complex and progressive cognitive and movement disorders. The clinical features were similar across all patients, and the study identified a recognizable clinical pattern that will help clinicians diagnose this disease. Ankündigung • Oct 11
Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering Centogene N.V. announced the expansion of MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis. CENTOGENE’s MOx 2.0 is a single-step multiomic solution that combines DNA sequencing, biochemical testing, and now RNA sequencing to provide physicians with the most comprehensive testing capability. Transcriptomics examines the transcripts to reveal mutation-specific RNA patterns, differences in gene expression, and how cells and tissues respond to environmental or physiological changes. Using RNA sequencing, a more complete picture of disease biology and response to drugs can be established. MOx 2.0 – A Paradigm Shift in Real-World Patient Diagnostics: CENTOGENE’s enhanced multiomic portfolio consists of three seamlessly integrated key updates: Highest Diagnostic Yield With Transcriptomics: By integrating RNA sequencing, a more complete picture of disease biology can be established, capturing over an estimated 60% of tested patients with suspected genetic disorders, compared to 40-50% with standard Whole Exome and Genome Sequencing. Simplified Logistics: Leveraging CentoCard®, CENTOGENE’s filter card technology for extracting high-quality extraction of DNA, RNA, enzymes, and metabolites from dried blood spots, sample collection and shipping has been streamlined – ensuring accessible multiomic testing for patients worldwide. Unparalleled Insights: Delivering medical reporting based on bioinformatics, artificial intelligence, and medical expert-based analysis of the CENTOGENE Biodatabank with over 800,000 patients represented from over 120 highly diverse countries, as well as more than 70 million unique variants. New Risk • Sep 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 6.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€29m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-€15m). Earnings are forecast to decline by an average of 6.3% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable next year (€46m net loss next year). Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Market cap is less than US$100m (US$29.5m market cap). Ankündigung • Sep 08
Centogene N.V. Reaffirms Revenue Guidance for the Year 2023 Centogene N.V. reaffirmed revenue guidance for the year 2023. The company reaffirms its guidance for 2023 annual revenue growth between 10-15% versus fiscal year 2022 revenues as revised. Ankündigung • Sep 02
Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients Centogene N.V. announced data confirming the utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher disease (GD). The findings from this landmark study which were published in Diagnostics in a paper titled, “Insights into the value of lyso-Gb1 as a predictive biomarker in treatment-naïve patients with Gaucher disease type 1 in the LYSO-PROOF study,” also indicate lyso-Gb1 could help to predict the clinical course of patients and improve personalized care of GD patients in the future. The study, which included 160 treatment-naïve GD patients from Israel, Russia, Pakistan, Egypt, Iran, Morocco, Algeria, India, Spain, Albania, Greece, Sweden, Columbia, and Tunisia, is one of the largest studies to examine Gaucher patients who have never received disease-specific treatment. CENTOGENE utilized CentoCard®, the Company’s proprietary, CE-marked dried blood spot (DBS) collection kit in combination with state-of-the-art biochemical and sequencing technologies to screen for mutations in the GBA1 gene and establish a GD diagnosis. The insights gained were powered by the CENTOGENE Biodatabank, the world’s largest real-world integrated multiomic data repository in rare and neurodegenerative diseases. The results of the study revealed a highly significant correlation between lyso-Gb1 and disease severity in all Gaucher patients, including those with novel rare GBA1 variants. Ankündigung • Aug 19
Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board Centogene N.V. announced Berndt Modig’s decision to resign from the company’s Supervisory Board, effective August 15, 2023. Mr. Modig’s resignation was not the result of any disagreement with the Company, and was in alignment with his intention announced on November 21, 2022 to transition off the Supervisory Board. Ankündigung • Jul 13
Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort Centogene N.V. announced the publication of a landmark study titled, "At a glance: the largest Niemann-Pick type C1 cohort with 602 patients diagnosed over 15 years." Recently published in the European Journal of Human Genetics, one of the world's leading medical genetic journals, the study represents the largest and most heterogeneous Niemann-Pick typeC1 disease (NPC1) cohort, with 602 patients referred from 47 countries. NPC1 is a rare and severe autosomal recessive disorder, characterized by a range of neurovisceral clinical manifestations and a fatal outcome with no effective treatment to date. To gain a deeper understanding of the disease, researchers carried out an analysis using the CENTOGENE Biodatabank, which included clinical, genetic, and biomarker data from NPC1 patients from the past 15 years. The study's findings reveal groundbreaking insights into the clinical and metabolic patterns of NPC1 disease. The analysis of the data captured in the CENTOGENE Biodatabank revealed 287 unique Pathogenic/Likely Pathogenic (P/LP) variants, with 73 having not been described previously. Additionally, researchers identified variant-linked patterns of symptoms and manifestations by leveraging Human Phenotype Ontology (HPO) terms. Furthermore, these results suggest that in addition to its utility to classify and report variants, the biomarker N-palmitoyl-O-phosphocholineserine ((PPCS), formerly known as lyso-SM-509), might serve to indicate disease severity/progression. In analyzing the data, CENTOGENE was able to establish novel genotype-phenotype relationships and illustrate the value of combined genetic and biomarker testing to diagnose and increase the understanding of NPC1. Ankündigung • Jun 29
Centogene N.V. announced that it expects to receive $30 million in funding from Lifera Centogene N.V. announced a private placement to issue convertible loan for gross proceeds of $30 million on June 27, 2023. The transaction will include participation from new investor, Lifera. The loan will be convertible before 2024 into common stock at a conversion price of $2.20. New Risk • Jun 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€29m free cash flow). Share price has been highly volatile over the past 3 months (41% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€37m net loss in 2 years). Shareholders have been diluted in the past year (3.0% increase in shares outstanding). Market cap is less than US$100m (US$44.0m market cap). Ankündigung • Jun 16
Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency Centogene N.V. announced that it has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC (“Nasdaq”) dated June 8, 2023, indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) set forth in the Nasdaq Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(3)(C) requires companies to maintain a minimum MVPHS of USD 15 million, and Listing Rule 5810(c)(3)(D) provides that a failure to meet the MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the MVPHS of the Company for the 30 consecutive business days from April 26, 2023 to June 7, 2023, the Company no longer meets the MVPHS minimum requirement. This notification does not impact the listing and trading of the Company’s securities at this time. Pursuant to Nasdaq Listing Rule 5810(c)(3)(D), the Company has a compliance period of 180 calendar days (or until December 5, 2023) to regain compliance. If at any time during this compliance period the Company’s MVPHS closes at USD 15 million or more for a minimum of ten consecutive business days, Nasdaq will notify the Company that it has achieved compliance with the MVPHS requirement, and the MVPHS matter will be closed. As previously announced, the Company also has a separate Nasdaq Global Market deficiency in the requirement that it maintain a minimum bid price of USD 1.00 for its common shares listed on Nasdaq ("MBP"). The Company has until October 23, 2023 to regain compliance with the MBP requirement. In the event the Company does not regain compliance with Rule 5450(b)(3)(C) prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor its market value between now and December 5, 2023. Ankündigung • Jun 14
Centogene N.V., Annual General Meeting, Jun 30, 2023 Centogene N.V., Annual General Meeting, Jun 30, 2023, at 14:00 Central European Standard Time. Location: the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands. Amsterdam Netherlands Agenda: To discuss Extension of the period for drawing up the Dutch statutory annual accounts and board report for the financial year ended December 31, 2022; to discuss Instruction to Ernst & Young Accountants LLP for the external audit of the Company; to discuss Discussion of the Company's dividend and reservation policy; to Appointment of Prof. Dr. Peter Andreas Bauer as managing director of the Company; to discuss Appointment of Mary Blake Sheahan as supervisory director of the Company; to Reappointment of Peer Michael Schatz as supervisory director of the Company; and to discuss other matters. Ankündigung • May 20
Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023 Centogene N.V. announced that Bettina Goerner, Chief Data Officer (CDO), has decided to step down from her role, effective May 26. Reported Earnings • May 17
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: €1.45 loss per share (improved from €2.09 loss in FY 2021). Revenue: €47.5m (down 75% from FY 2021). Net loss: €38.7m (loss narrowed 17% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 28%. Ankündigung • May 17
Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023 Centogene N.V. provided revenue guidance for 2023. The Company expects revenue growth to be between 10 to 15% in FY2023 compared to FY2022. Ankündigung • Feb 08
Centogene Regains Compliance with Nasdaq Listing Requirements On February 7, 2023, Centogene N.V. announced that it has received a notification from the Nasdaq Stock Market LLC (‘Nasdaq’) Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1). As a result, CENTOGENE is now compliant with all applicable Nasdaq listing standards, and Nasdaq considers this matter closed. CENTOGENE was previously notified by Nasdaq on December 12, 2022, that it was not in compliance with the minimum bid price rule, because its common stock failed to meet the closing bid price of USD 1.00 or more for 30 consecutive business days. To regain compliance with the minimum bid price rule, the Company was required to maintain a minimum closing bid price of USD 1.00 for at least 10 consecutive business days. This requirement was met on February 3, 2023. Ankündigung • Jan 31
Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH Centogene N.V. announced that Prof. Peter Bauer, M.D., the Company’s Chief Medical and Genomic Officer, has been appointed to the Management Board of Centogene N.V. as of January 24, 2023, to be confirmed at the Company’s next General Meeting of Shareholders. Prof. Bauer has also been appointed as Managing Director of the subsidiary Centogene GmbH. Prof. Bauer has been serving as CENTOGENE's Chief Medical and Genomic Officer since 2022. In this role, he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments—turning medical questions into complete and fast analytical processes and ensuring that medically-driven results are brought to clinicians and patients immediately. Prof. Bauer originally joined CENTOGENE in 2016 and has since held a variety of management positions within the Company, including operations as well as innovation and research related roles. Prof. Bauer received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Prof. Bauer has authored more than 250 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology. Ankündigung • Jan 20
Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023 Centogene N.V. announced that Dr. Florian Vogel, Chief Process Officer (CPO) has decided to step down from his role, effective February 28. Ankündigung • Jan 12
Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics Twist Bioscience Corporation and Centogene N.V. announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and support diagnostics. Target enrichment panels enable more in-depth sequencing on target genes, reducing the need for comprehensive sequencing. This allows for more sensitive detection of target genetic sequences and provides higher confidence that variants will be detected, further driving the understanding of diseases and supporting healthcare professionals in providing precision medicine. Labs and research institutions can purchase these ready-made panels to help accelerate their research, and also have the option of using CENTOGENE’s CentoCloud® for the identification, prioritization, and classification of human genetic variants to expedite diagnostic analysis. All three new Alliance Panels are highly curated using the CENTOGENE Biodatabank, with nearly 700,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. Identified sequences are then synthesized by Twist as biotinylated capture probes which are compatible with Twist’s library preparation solution and target enrichment workflows. The panels offered through Twist will include: The Twist Alliance CNTG Exome Panel, which enables whole exome analysis of genetic markers relevant to rare diseases. The Twist Alliance CNTG Rare Disease Panel, which offers analysis of focused rare-disease-related sequences and The Twist Alliance CNTG Hereditary Oncology Panel, which enables the detection of biomarkers that indicate a high risk of developing cancer. Reported Earnings • Dec 23
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: €0.44 loss per share (further deteriorated from €0.37 loss in 2Q 2021). Revenue: €11.2m (down 78% from 2Q 2021). Net loss: €11.9m (loss widened 48% from 2Q 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 8.6%. Revenue is expected to decline by 56% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 13%. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jul 16
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2022 results: €0.49 loss per share (down from €0.22 loss in 1Q 2021). Revenue: €10.3m (down 84% from 1Q 2021). Net loss: €11.1m (loss widened 127% from 1Q 2021). Revenue missed analyst estimates by 64%. Earnings per share (EPS) exceeded analyst estimates by 44%. Over the next year, revenue is expected to shrink by 73% compared to a 39% growth forecast for the industry in the US. Reported Earnings • Apr 02
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: €2.09 loss per share (down from €1.02 loss in FY 2020). Revenue: €189.9m (up 48% from FY 2020). Net loss: €46.9m (loss widened 119% from FY 2020). Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 69% compared to a 66% growth forecast for the pharmaceuticals industry in the US. Major Estimate Revision • Apr 01
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €52.2m to €59.5m. EPS estimate fell from -€1.51 to -€1.59 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target broadly unchanged at US$13.88. Share price rose 3.4% to US$4.25 over the past week. Reported Earnings • Nov 26
Third quarter 2021 earnings: EPS and revenues exceed analyst expectations Third quarter 2021 results: €0.96 loss per share (down from €0.27 loss in 3Q 2020). Revenue: €30.2m (down 17% from 3Q 2020). Net loss: €21.6m (loss widened 279% from 3Q 2020). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 96%. Earnings per share (EPS) surpassed analyst estimates by 96%. Over the next year, revenue is expected to shrink by 59% compared to a 471% growth forecast for the industry in the US. Major Estimate Revision • Nov 25
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €164.5m to €176.5m. Forecast EPS reduced from -€1.60 to -€2.41 per share. Biotechs industry in the US expected to see average net income decline 10.0% next year. Consensus price target down from US$26.03 to US$20.27. Share price fell 23% to US$7.20 over the past week. Reported Earnings • Sep 09
Second quarter 2021 earnings released: €0.37 loss per share (vs €0.52 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: €51.9m (up 434% from 2Q 2020). Net loss: €8.02m (loss narrowed 23% from 2Q 2020). Executive Departure • Aug 18
Chief Scientific Officer Philip Lambert has left the company On the 16th of August, Philip Lambert's tenure as Chief Scientific Officer ended after 1.7 years in the role. We don't have any record of a personal shareholding under Philip's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Jul 01
Executive Officer Richard Stoffelen has left the company On the 30th of June, Richard Stoffelen's tenure as Executive Officer ended after less than a year in the role. As of March 2021, Richard still personally held 119.80k shares (US$2.4m worth at the time). Richard is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model. Major Estimate Revision • Jun 23
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €136.7m to €145.5m. Forecast EPS reduced from -€1.00 to -€1.31 per share. Biotechs industry in the US expected to see average net income decline 5.1% next year. Consensus price target down from US$20.01 to US$19.17. Share price fell 4.6% to US$10.06 over the past week. Reported Earnings • Jun 19
First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: €65.0m (up 437% from 1Q 2020). Net loss: €4.89m (loss narrowed 44% from 1Q 2020). Major Estimate Revision • Apr 24
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from €78.1m to €136.7m. EPS estimate unchanged from -€1.00 at last update. Biotechs industry in the US expected to see average net income growth of 3.4% next year. Consensus price target broadly unchanged at US$20.35. Share price fell 6.2% to US$10.80 over the past week. Reported Earnings • Apr 18
Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: €128.4m (up 163% from FY 2019). Net loss: €21.4m (loss widened 2.5% from FY 2019).